The latest price target for Nautilus Biotechnology (NASDAQ:NAUT) was reported by Guggenheim on June 27, 2024. The analyst firm set a price target for $6.00 expecting NAUT to rise to within 12 months (a possible 142.91% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Nautilus Biotechnology (NASDAQ:NAUT) was provided by Guggenheim, and Nautilus Biotechnology initiated their buy rating.

There is no last upgrade for Nautilus Biotechnology

There is no last downgrade for Nautilus Biotechnology.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nautilus Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nautilus Biotechnology was filed on June 27, 2024 so you should expect the next rating to be made available sometime around June 27, 2025.

While ratings are subjective and will change, the latest Nautilus Biotechnology (NAUT) rating was a initiated with a price target of $0.00 to $6.00. The current price Nautilus Biotechnology (NAUT) is trading at is $2.47, which is within the analyst’s predicted range.